Niktimvo

Asset

Blocks CSF1R signaling to reduce macrophage-mediated inflammation and fibrosis.

Stage: Discontinued
Modality: Antibody
Target: Inflammation; 1
Indication: 0
Trials: 1
Developer

Indications

1

Idiopathic pulmonary fibrosis
Discontinued, endpoints.news, 13 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners1
Evidence for its targets2
Competitors9
Aging relevance1
Signals2

Every asset’s record: target, stage, trials and the evidence behind it.